Apis Partners to invest in L&T IFD, aims for a 25% stake worth $110M
Category: #headlines  By Pankaj Singh  Date: 2019-04-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Apis Partners to invest in L&T IFD, aims for a 25% stake worth $110M

Apis Partners has signed a binding agreement for the acquisition of the stake and will be investing through one of its funds called Apis Growth Fund II.

UK-based venture capital firm Apis Partners has reportedly announced plans to acquire a 25 per cent stake in L&T Financial Holdings arm L&T IDF (Infra Debt Fund), for US$110 million.

Apparently, the proposed investment is aimed at supporting the growth of the loan book of L&T IDF across various sectors including renewable energy, airports, power transmission, roads and ports. In addition, the funding is likely to consolidate IDF’s technology, capital structure and digitization strategy. For those uninitiated, L&T IDF holds a loan book worth Rs. 8,000 crore.

Authentic sources reported that about 70% of the investment is growth capital for L&T IDF, while 30% would be deployed for a secondary transaction in which shareholders will exit their holdings. Sources further claimed that the partnership with Apis is anticipated to help IDF with gaining access to low-cost international fund sources that will be deployed for refinancing operational infrastructure projects in India.

L&T IDF’s Chief Executive Shiva Rajaraman stated that the Indian infrastructure market provides significant growth prospects for specialized re-financiers such as L&T IDF. He added that the company’s IDF platform will be in a better position to utilize these opportunities through the partnership with Apis Partners and remain a leader in key areas of the infrastructure refinancing space.

Dinanath Dubhashi, the Chief Executive & Managing Director of LTFH (L&T Finance Holdings), an IDF promoter, was reportedly quoted saying that the latest alliance with Apis reflects the value creation offered by India’s infrastructure financing space to the investors who keep looking for long-term sustainable returns. Apis Partners’ Managing Partner & Co-founder, Udayan Goyal, claimed that IDF holds an exceptional track record for refinancing high-potential infrastructure projects as well as raising funds at competitive rates.

Source Credits: https://www.businesstoday.in/top-story/apis-partners-plans-to-pick-25-stake-for-110-million-in-lt-infra-debt-fund/story/340410.html

https://www.thehindubusinessline.com/markets/lt-idf-to-raise-110-mn-from-apis-partners/article26943088.ece

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
By Pankaj Singh

The manuscript includes data of the first four trial participants that were treated with RP-L102 under the Phase 1/2 FANCOLEN-I study.   First RP-L102 trail data demonstrates increase in bone marrow engraftment levels, which further leads to...

Shopify buys 6 River Systems for $450M to grow its fulfillment network
Shopify buys 6 River Systems for $450M to grow its fulfillment network
By Pankaj Singh

Acquisition of 6 River Systems seems to be an attempt to accelerate the growth in delivery of daily packages. The deal would further expand the reach of the Shopify Fulfillment Network, which utilizes machine learning to ensure lower shipping cost...

Genentech to present new data from neuroscience portfolio at ECTRIMS
Genentech to present new data from neuroscience portfolio at ECTRIMS
By Pankaj Singh

The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.   The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neur...